FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892110441> ?p ?o ?g. }

• W2892110441 endingPage "8010" @default.
• W2892110441 startingPage "8010" @default.
• W2892110441 abstract "8010 Background: Pembrolizumab (pembro) is a monoclonal antibody against PD-1 that helps to restore antitumor immune surveillance. KEYNOTE-023 (NCT02036502) is a phase 1 dose-escalation study evaluating safety and efficacy of pembro in combination with lenalidomide (len) and low-dose dexamethasone (dex) in patients with RRMM. Methods: Patients with RRMM who failed ≥ 2 prior therapies enrolled. Modified 3 + 3 design was used for dose determination with cohorts of 3-6 patients treated with pembro 2 mg/kg Q2W + len 10 mg or 25 mg on days 1-21 and dex 40 mg weekly, repeated every 28 days. After preliminary MTD/MAD identification, additional patients received pembro 200 mg Q2W + len and dex for dose confirmation. Upon final MTD, patients enrolled in the dose expansion phase. Treatment continued for 24 mo or until confirmed disease progression or unacceptable toxicity. Response evaluated monthly using IMWG 2006. Results: 3 DLTs from the pembro 2 mg/kg, 25-mg len cohort were observed in 17 patients in the dose determination/confirmation phase: grade 3/grade 4 neutropenia, grade 3 pneumonia, and grade 3 tumor lysis syndrome with grade 4 hyperuricemia. Based on dose confirmation phase, pembro 200 mg + len 25 mg and dex 40 mg was the MTD/MAD. As of Sep 22, 2015, an additional 33 patients were enrolled in the expansion phase. Median age for the total population was 62 y, 72% had ≥ 3 prior therapies, 76% were refractory to len, and 30% had double refractory disease. 36 patients (72%) experienced treatment-related AEs, most commonly thrombocytopenia (28%) and neutropenia (24%). With a median follow-up of 9.7 mo (range, 4.3-18.4), 13/17 (76%) patients evaluated for efficacy in dose determination/confirmation responded to treatment, including 4 VGPRs (2 in len-refractory) and 9 PRs (3 in len-refractory), with median duration of response 9.7 mo (range, 0+-16.7+). 3 patients (18%) had stable disease. 94% had a reduction in M protein or free light chains. Updated efficacy data for all 50 patients will be presented. Conclusions: Pembro in combination with len and dex was associated with a tolerable safety profile and promising antimyeloma activity in heavily pretreated patients with RRMM. Clinical trial information: NCT02036502." @default.
• W2892110441 created "2018-09-27" @default.
• W2892110441 creator A5008759843 @default.
• W2892110441 creator A5020123690 @default.
• W2892110441 creator A5023752321 @default.
• W2892110441 creator A5029159537 @default.
• W2892110441 creator A5038208984 @default.
• W2892110441 creator A5038235561 @default.
• W2892110441 creator A5043490010 @default.
• W2892110441 creator A5045740077 @default.
• W2892110441 creator A5047073941 @default.
• W2892110441 creator A5052641327 @default.
• W2892110441 creator A5057254430 @default.
• W2892110441 creator A5069449708 @default.
• W2892110441 creator A5080959881 @default.
• W2892110441 date "2016-05-20" @default.
• W2892110441 modified "2023-10-01" @default.
• W2892110441 title "Pembrolizumab in combination with lenalidomide and low-dose dexamethasone for relapsed/refractory multiple myeloma (RRMM): Final efficacy and safety analysis." @default.
• W2892110441 doi "https://doi.org/10.1200/jco.2016.34.15_suppl.8010" @default.
• W2892110441 hasPublicationYear "2016" @default.
• W2892110441 type Work @default.
• W2892110441 sameAs 2892110441 @default.
• W2892110441 citedByCount "36" @default.
• W2892110441 countsByYear W28921104412016 @default.
• W2892110441 countsByYear W28921104412017 @default.
• W2892110441 countsByYear W28921104412018 @default.
• W2892110441 countsByYear W28921104412019 @default.
• W2892110441 countsByYear W28921104412020 @default.
• W2892110441 countsByYear W28921104412021 @default.
• W2892110441 countsByYear W28921104412022 @default.
• W2892110441 countsByYear W28921104412023 @default.
• W2892110441 crossrefType "journal-article" @default.
• W2892110441 hasAuthorship W2892110441A5008759843 @default.
• W2892110441 hasAuthorship W2892110441A5020123690 @default.
• W2892110441 hasAuthorship W2892110441A5023752321 @default.
• W2892110441 hasAuthorship W2892110441A5029159537 @default.
• W2892110441 hasAuthorship W2892110441A5038208984 @default.
• W2892110441 hasAuthorship W2892110441A5038235561 @default.
• W2892110441 hasAuthorship W2892110441A5043490010 @default.
• W2892110441 hasAuthorship W2892110441A5045740077 @default.
• W2892110441 hasAuthorship W2892110441A5047073941 @default.
• W2892110441 hasAuthorship W2892110441A5052641327 @default.
• W2892110441 hasAuthorship W2892110441A5057254430 @default.
• W2892110441 hasAuthorship W2892110441A5069449708 @default.
• W2892110441 hasAuthorship W2892110441A5080959881 @default.
• W2892110441 hasConcept C121332964 @default.
• W2892110441 hasConcept C121608353 @default.
• W2892110441 hasConcept C126322002 @default.
• W2892110441 hasConcept C142424586 @default.
• W2892110441 hasConcept C143998085 @default.
• W2892110441 hasConcept C197934379 @default.
• W2892110441 hasConcept C2776063141 @default.
• W2892110441 hasConcept C2776364478 @default.
• W2892110441 hasConcept C2777063308 @default.
• W2892110441 hasConcept C2777701055 @default.
• W2892110441 hasConcept C2778375690 @default.
• W2892110441 hasConcept C2780057760 @default.
• W2892110441 hasConcept C2780401358 @default.
• W2892110441 hasConcept C2908647359 @default.
• W2892110441 hasConcept C29730261 @default.
• W2892110441 hasConcept C71924100 @default.
• W2892110441 hasConcept C87355193 @default.
• W2892110441 hasConcept C99454951 @default.
• W2892110441 hasConceptScore W2892110441C121332964 @default.
• W2892110441 hasConceptScore W2892110441C121608353 @default.
• W2892110441 hasConceptScore W2892110441C126322002 @default.
• W2892110441 hasConceptScore W2892110441C142424586 @default.
• W2892110441 hasConceptScore W2892110441C143998085 @default.
• W2892110441 hasConceptScore W2892110441C197934379 @default.
• W2892110441 hasConceptScore W2892110441C2776063141 @default.
• W2892110441 hasConceptScore W2892110441C2776364478 @default.
• W2892110441 hasConceptScore W2892110441C2777063308 @default.
• W2892110441 hasConceptScore W2892110441C2777701055 @default.
• W2892110441 hasConceptScore W2892110441C2778375690 @default.
• W2892110441 hasConceptScore W2892110441C2780057760 @default.
• W2892110441 hasConceptScore W2892110441C2780401358 @default.
• W2892110441 hasConceptScore W2892110441C2908647359 @default.
• W2892110441 hasConceptScore W2892110441C29730261 @default.
• W2892110441 hasConceptScore W2892110441C71924100 @default.
• W2892110441 hasConceptScore W2892110441C87355193 @default.
• W2892110441 hasConceptScore W2892110441C99454951 @default.
• W2892110441 hasIssue "15_suppl" @default.
• W2892110441 hasLocation W28921104411 @default.
• W2892110441 hasOpenAccess W2892110441 @default.
• W2892110441 hasPrimaryLocation W28921104411 @default.
• W2892110441 hasRelatedWork W2003305967 @default.
• W2892110441 hasRelatedWork W2051109119 @default.
• W2892110441 hasRelatedWork W2091675597 @default.
• W2892110441 hasRelatedWork W2118465399 @default.
• W2892110441 hasRelatedWork W2192430028 @default.
• W2892110441 hasRelatedWork W2208379272 @default.
• W2892110441 hasRelatedWork W2430400806 @default.
• W2892110441 hasRelatedWork W2531713994 @default.
• W2892110441 hasRelatedWork W3195616002 @default.
• W2892110441 hasRelatedWork W3217566318 @default.
• W2892110441 hasVolume "34" @default.
• W2892110441 isParatext "false" @default.
• W2892110441 isRetracted "false" @default.

• next